Safety and Tolerability Trial of Arimoclomol for Sporadic Inclusion Body Myositis

Trial Profile

Safety and Tolerability Trial of Arimoclomol for Sporadic Inclusion Body Myositis

Completed
Phase of Trial: Phase II/III

Latest Information Update: 21 Jun 2016

At a glance

  • Drugs Arimoclomol (Primary)
  • Indications Inclusion body myositis
  • Focus Adverse reactions
  • Most Recent Events

    • 05 May 2014 New trial record
    • 03 May 2014 Results presented at the 66th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top